3 Year Absolute Returns
80.69% ↑
NAV (₹) on 05 Nov 2026
17.30
1 Day NAV Change
0.70%
Risk Level
Very High Risk
Rating
-
Aditya Birla Sun Life Nifty Healthcare ETF is a Equity mutual fund categorized under ETF, offered by Aditya Birla Sun Life AMC Limited. Launched on 08 Oct 2021, investors can start with a lumpsum ... Read more
AUM
₹ 74.67 Cr
| Sectors | Weightage |
|---|---|
| Pharmaceuticals | 81.10% |
| Hospitals & Medical Services | 18.86% |
| Treps/Reverse Repo | 0.71% |
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 17.00% | ₹ 12.69 | Pharmaceuticals |
| Divi's Laboratories Ltd. | 10.46% | ₹ 7.81 | Pharmaceuticals |
| Apollo Hospitals Enterprise Ltd. | 7.45% | ₹ 5.56 | Hospitals & Medical Services |
| Laurus Labs Ltd. | 6.81% | ₹ 5.09 | Pharmaceuticals |
| Cipla Ltd. | 6.69% | ₹ 5 | Pharmaceuticals |
| Dr. Reddy's Laboratories Ltd. | 6.64% | ₹ 4.96 | Pharmaceuticals |
| Torrent Pharmaceuticals Ltd. | 6.26% | ₹ 4.68 | Pharmaceuticals |
| Max Healthcare Institute Ltd. | 6.11% | ₹ 4.56 | Hospitals & Medical Services |
| Lupin Ltd. | 4.35% | ₹ 3.25 | Pharmaceuticals |
| Aurobindo Pharma Ltd. | 4.08% | ₹ 3.05 | Pharmaceuticals |
| Fortis Healthcare Ltd. | 3.54% | ₹ 2.65 | Hospitals & Medical Services |
| Glenmark Pharmaceuticals Ltd. | 3.10% | ₹ 2.31 | Pharmaceuticals |
| Alkem Laboratories Ltd. | 2.77% | ₹ 2.07 | Pharmaceuticals |
| Zydus Lifesciences Ltd. | 2.54% | ₹ 1.90 | Pharmaceuticals |
| Mankind Pharma Ltd. | 2.50% | ₹ 1.87 | Pharmaceuticals |
| IPCA Laboratories Ltd. | 2.36% | ₹ 1.76 | Pharmaceuticals |
| Biocon Ltd. | 2.28% | ₹ 1.70 | Pharmaceuticals |
| Gland Pharma Ltd. | 2.04% | ₹ 1.52 | Pharmaceuticals |
| Krishna Institute of Medical Sciences Ltd. | 1.76% | ₹ 1.31 | Hospitals & Medical Services |
| Abbott India Ltd. | 1.22% | ₹ 0.91 | Pharmaceuticals |
| TREPS | 0.71% | ₹ 0.53 | Others |
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | 18.45% | 14.24% | 8.48% | 21.80% |
| Category returns | -0.06% | 0.38% | 3.95% | 18.32% |
The investment objective of the scheme is to provide returns that before expenses, closely correspond to the total returns of securities as represented by Nifty Healthcare TRI, subject to tracking ... Read more
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Aditya Birla Sun Life Silver ETF
ETF
Regular
|
₹186.01 | 27.62% | 157.66% | 0.00% | ₹2,826 | 0.35% |
Very High
|
|
ICICI Prudential Silver ETF
ETF
Regular
|
₹185.82 | 27.56% | 157.48% | 0.00% | ₹14,341 | 0.40% |
Very High
|
|
Kotak Silver ETF
ETF
Regular
|
₹18.07 | 27.56% | 156.98% | 0.00% | ₹3,712 | 0.35% |
Very High
|
|
Mirae Asset Silver ETF
ETF
Regular
|
₹181.64 | 27.51% | 156.90% | 0.00% | ₹1,173 | 0.35% |
Very High
|
|
DSP Silver ETF
ETF
Regular
|
₹17.91 | 27.18% | 156.23% | 0.00% | ₹1,366 | N/A |
Very High
|
|
Nippon India Silver ETF
ETF
Regular
|
₹178.11 | 27.25% | 155.53% | 0.00% | ₹31,196 | N/A |
Very High
|
|
HDFC Silver ETF
ETF
Regular
|
₹178.14 | 26.95% | 154.57% | 0.00% | ₹7,724 | 0.50% |
Very High
|
|
UTI Silver Exchange Traded Fund
ETF
Regular
|
₹179.89 | 27.73% | 154.14% | 0.00% | ₹1,487 | 0.59% |
Very High
|
|
Axis Silver ETF
ETF
Regular
|
₹185.47 | 27.59% | 153.90% | 0.00% | ₹2,028 | 0.42% |
Very High
|
|
Mirae Asset NYSE FANG + ETF
ETF
Regular
|
₹154.54 | 6.55% | 144.46% | 161.50% | ₹4,448 | 0.66% |
Very High
|
What is the current NAV of Aditya Birla Sun Life Nifty Healthcare ETF Regular Growth?
What is the fund size (AUM) of Aditya Birla Sun Life Nifty Healthcare ETF Regular Growth?
What are the historical returns of Aditya Birla Sun Life Nifty Healthcare ETF Regular Growth?
What is the risk level of Aditya Birla Sun Life Nifty Healthcare ETF Regular Growth?
What is the minimum investment amount for Aditya Birla Sun Life Nifty Healthcare ETF Regular Growth?
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article